Background: Trastuzumab (HerceptinÒ) improves disease-free survival (DFS) and overall survival for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess the magnitude of its clinical benefit for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study.
introduction Trastuzumab (HerceptinÒ) has been shown in several large randomized clinical trials [1, 2, 3, 4] to be highly effective in reducing the risk of relapse and death for patients with HER2-positive early breast cancer. In these studies, adjuvant trastuzumab improved disease-free survival (DFS) when compared with the respective control groups without trastuzumab therapy for the various patient subgroups examined. Recently, the Herceptin Adjuvant (HERA) trial published results at 2 years of median follow-up showing that 1 year of treatment with trastuzumab administered following completion of all neoadjuvant and/or adjuvant chemotherapy, and radiotherapy if indicated, provided a statistically significant improvement in overall survival [Hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.47-0.91; P = 0.0115] and DFS (HR 0.64; 95% CI 0.54-0.76; P < 0.0001) [5] . While it is clear that trastuzumab is an effective adjuvant therapy, questions remain regarding whether the magnitude of the benefit derived from adjuvant trastuzumab is sufficiently large to justify its routine use for all subgroups of patients with HER2-positive early breast cancer, in view of its economic cost and the risks of cardiac damage [6] . Risk and benefit may also differ across subgroups over time, and such differences may be relevant to treatment decisions. In order to further inform this assessment, we examined the magnitude of the benefit of trastuzumab therapy within various subgroups of the HERA trial population, especially as defined by steroid hormone receptor status and nodal status. To supplement the whisker plot displays of the relative risk reduction already described with trastuzumab in various subgroups [5] , we also present estimates of the absolute differences in 3-year DFS. Finally, we examined the hazard function plots to study the time course of events for different subgroups and explore when during the course of follow-up trastuzumab showed most influence on the risk of relapse.
patients and methods
HERA is an international multicentre randomized trial comparing 1 or 2 years of trastuzumab treatment with observation alone after standard neoadjuvant or adjuvant chemotherapy in women with HER2-positive node-positive or high-risk node-negative breast cancer. In total, 5102 women participated in the trial. The HERA data set reported by Smith et al. [5] used for this report comprised data from 1703 women who had been randomized for treatment with trastuzumab for 1 year and 1698 women from the observation group, with median follow-up of 23.5 months (range 0-48 months). The 2-year trastuzumab group remains blinded as the comparison of 1 year versus 2 years of trastuzumab is continuing to be monitored by the independent data monitoring committee.
The primary endpoint of the trial was DFS defined as time from randomization to the first occurrence of any of the following events: recurrence of breast cancer at any site, the development of ipsilateral or contralateral breast cancer including ductal carcinoma in situ but not lobular carcinoma in situ, second nonbreast malignant disease other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, or death from any cause without documentation of a cancerrelated event. We calculated Kaplan-Meier [7] estimates for DFS curves for subgroups and estimated standard errors and 95% CIs according to the Greenwood formula [8] . Hazard function estimates [9] were calculated using the data in six monthly intervals to provide annualized event rates-the proportion of patients estimated to experience a DFS event per year of follow-up.
Hormone receptor status [estrogen (ER) or progesterone (PgR)] was assessed through the data collected in the case report form on the basis of local assessment with positive or negative status defined according to criteria applied by the local pathologist.
The trial was sponsored and funded by Roche. The collection, analysis, and interpretation of the data were done entirely independently, under the auspices of the Breast International Group. RDG and MU led the writing of the paper with input from the HERA executive committee, which includes three Roche representatives who were not allowed to influence the paper in any way other than as approved by the executive committee. All authors had access to all the data. The trial's steering committee had final responsibility to submit the manuscript for publication.
results Figure 1 shows the DFS hazard function whisker plot for the group as a whole and for subgroups according to steroid hormone receptor status and nodal status. At 23.5 months of median follow-up, the relative risk reduction estimates for the overall cohort and for subgroups indicate consistent reductions in the risk of relapse with no evidence that the HR in any subgroup differed from that observed overall. Table 1 extends this analysis to show the 3-year DFS percentages and the relative HR estimates for selected patient subgroups. Excluding the small cohort of patients who received neoadjuvant chemotherapy (in whom tumor size and nodal status are therefore not assessable), all groups showed an improvement in estimated 3-year DFS, though with the estimates of the magnitude of absolute improvement ranging fairly widely from 0.6% for patients with hormone receptornegative, node-negative disease (HR = 0.68) to 11.3% for patients with hormone receptor-positive, node-negative disease (HR = 0.46). The protocol specified that patients with nodenegative disease were eligible only if the pathologic tumor size exceeded 1 cm; in fact 90.4% of the node-negative cohort (994 of 1099 patients) was known to have tumors >1 cm in diameter. Results for the 510 patients with node-negative disease and tumors ranging from 1.1 to 2.0 cm in diameter are Table 1 and demonstrate that the benefit of trastuzumab effect appears to extend even to this relatively favorable prognosis subgroup. Figure 2 shows Kaplan-Meier curves and hazard function plots comparing 1 year of trastuzumab versus observation for subgroups defined by hormone receptor status and nodal status. The observation group among the hormone receptornegative cohort (both ER and PgR reported as negative) experienced a very high risk of early recurrence, which was reduced for the trastuzumab group. Among patients with negative hormone receptors, the risk of relapse declined substantially during the second and third years of follow-up for the observation group and during the third year of follow-up for the trastuzumab group. By contrast, for the hormone receptor-positive cohort, the risk of relapse for both treatment and observation groups was relatively consistent over time, with the trastuzumab treatment effect apparent both early and later during follow-up.
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discussion
Subgroup analyses must be interpreted with caution due to the increased likelihood of false-positive and false-negative results arising by the play of chance [10] . Such analyses, however, if prospectively defined and biologically motivated, should be available to inform assessment of potential benefits of treatment for subpopulations [10] . To reduce the risk of inflating false-positive results, we prospectively defined nodal status (a marker for risk of relapse-prognostic) and steroid hormone receptor status (a marker for potential differential treatment response-predictive) as factors of interest. Tumor grade was also suggested for subgroup analysis by the executive committee, but not included due to the difficulties to standardize grading across a large number of international clinical settings.
It is not the intent of these analyses to show 'significant' treatment effects in separate subgroups. In particular, failure to obtain a statistically significant P value within a subgroup should not be taken as evidence against trastuzumab for that subgroup. Rather, we provide estimates and 95% CIs for the magnitude of trastuzumab treatment effect (compared with observation following completion of any (neo)adjuvant chemotherapy) evident from various subgroups of the total HER2-positive patient population. Results were examined in terms of estimated relative treatment effect (HR estimated with 2 years of median follow-up), estimated absolute treatment effect (absolute percentage difference in predicted 3-year DFS percentage), and estimated hazard functions over time during the first 3 years after randomization. We note that the CIs for the estimated 3-year absolute effects tend to be wide and that differences among subgroups may be due to the play of chance. It is particularly relevant, however, to have some information from the patient cohorts thought to have a lower risk of relapse overall, as these are the subgroups for which the benefit-to-risk ratio might be challenged. For example, results for the cohort of women with node-negative disease are particularly useful as only the HERA and Breast Cancer International Research Group 006 studies included substantial numbers of these patients. We were unable to identify a subgroup for which the potential absolute benefit of trastuzumab was small enough to indicate that the treatment might not be clinically beneficial. Cost-benefit analysis [6] is beyond the scope of the present report, and acceptable limits will in any event differ internationally. However, even patients with node-negative disease gained substantially from use of trastuzumab, and indeed, among the node-negative cohort, those with small tumors still indicated a worthwhile benefit of treatment. Trastuzumab is likely to be meaningfully effective for all cohorts of patients included in the randomized trials.
In addition to nodal status and hormone receptor status, other factors might also be considered for subgroup analysis [5] . Patient age, for example, might be considered primarily on the basis of an apparent reduced effect of trastuzumab for women ‡60 years of age [5] . This observed result is statistically unreliable, however, due to the retrospective definition of the subgroup and the small number of patients included. Even if some age-related biologic factor is eventually shown to influence the magnitude of benefit from trastuzumab, denying this effective adjuvant therapy to patients on the basis of age alone is inappropriate; age is not a therapeutic target, though prior cardiac comorbidity could be relevant to the decision on trastuzumab therapy, and is likely to be more common among older patients.
Examining the magnitude of benefit according to molecularly defined subgroups holds promise to improve tailoring treatments for the future. For example, assessing treatment effects for the HER2-positive cohort according to the presence or absence of co-amplification of the c-Myc oncogene, the expression levels of PTEN (phosphatase and tensin homolog deleted on chromosome 10), and the presence or absence of p95HER2 receptor might be considered. Analyses according to each of these potential markers for anti-HER2 treatment responsiveness have been prospectively planned, e.g. in the recently launched international ALTTO (Adjuvant Lapatinib and Trastuzumab Treatment Optimization) study 
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which evaluates the role of 52 weeks of trastuzumab, lapatinib, their combination, and their sequence. Our analyses are limited by the fact that relatively few relapses have occurred and the 2-year follow-up is relatively short in the context of early-stage breast cancer. The HERA trial, as well as other large trials investigating trastuzumab in early breast cancer, reported the results earlier than the anticipated final analysis time point at the recommendation of the independent data monitoring committee. The observed treatment benefits were striking at the first interim analysis-both clinically and statistically. Furthermore, 50% of patients with endocrine responsive disease have the opportunity to respond to endocrine therapies, which may influence longer term outcomes. These two features make evaluation of the magnitude of trastuzumab effect within subgroups potentially more hazardous than usual. The results presented here should, therefore, not be overinterpreted.
Our analyses provide clear evidence that hormone receptornegative and hormone receptor-positive diseases have fundamentally different patterns of relapse. Even if estimates at a single point in follow-up indicate similar magnitude of treatment effects for these two cohorts, the pattern of treatment effects may differ over follow-up time. For the receptornegative cohort, trastuzumab substantially reduces the risk of early relapse, but the opportunity for later improvement is low as the observation group has a relatively low risk of relapse during later follow-up. By contrast, despite use of both chemotherapy and endocrine therapy, moderate risk of relapse persists over time for the receptor-positive cohort offering an opportunity for modest but sustained reduction in risk over time with trastuzumab. Thus, the receptor-negative cohort may have contributed disproportionately to the early results, which motivated reporting outcomes from HERA and the other large trastuzumab trials at a shorter follow-up than originally 
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